PL3678692T3 - Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy - Google Patents

Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy

Info

Publication number
PL3678692T3
PL3678692T3 PL18854165T PL18854165T PL3678692T3 PL 3678692 T3 PL3678692 T3 PL 3678692T3 PL 18854165 T PL18854165 T PL 18854165T PL 18854165 T PL18854165 T PL 18854165T PL 3678692 T3 PL3678692 T3 PL 3678692T3
Authority
PL
Poland
Prior art keywords
genotypes
stratification
diabetes
prevention
treatment
Prior art date
Application number
PL18854165T
Other languages
English (en)
Inventor
Anders Essen-Möller
Original Assignee
Diamyd Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab
Publication of PL3678692T3 publication Critical patent/PL3678692T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/042Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Rehabilitation Therapy (AREA)
PL18854165T 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy PL3678692T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1751094 2017-09-08
EP18854165.0A EP3678692B1 (en) 2017-09-08 2018-09-10 Genotype stratification in diabetes treatment and prevention
PCT/SE2018/050904 WO2019050465A1 (en) 2017-09-08 2018-09-10 STRATIFICATION OF GENOTYPE IN THE TREATMENT AND PREVENTION OF DIABETES

Publications (1)

Publication Number Publication Date
PL3678692T3 true PL3678692T3 (pl) 2022-02-28

Family

ID=65634471

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21195581.0T PL3954384T3 (pl) 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
PL18854165T PL3678692T3 (pl) 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21195581.0T PL3954384T3 (pl) 2017-09-08 2018-09-10 Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy

Country Status (22)

Country Link
US (1) US20210077587A1 (pl)
EP (2) EP3678692B1 (pl)
JP (3) JP7337780B2 (pl)
KR (2) KR102781844B1 (pl)
CN (1) CN111372602A (pl)
CA (1) CA3074264A1 (pl)
CY (1) CY1124881T1 (pl)
DK (1) DK3678692T3 (pl)
EA (1) EA202090673A1 (pl)
ES (2) ES2902075T3 (pl)
HR (2) HRP20251067T1 (pl)
HU (2) HUE057216T2 (pl)
IL (2) IL273016B2 (pl)
LT (1) LT3678692T (pl)
MX (1) MX2020002462A (pl)
PL (2) PL3954384T3 (pl)
PT (1) PT3678692T (pl)
RS (2) RS67218B1 (pl)
SI (1) SI3678692T1 (pl)
SM (2) SMT202200009T1 (pl)
WO (1) WO2019050465A1 (pl)
ZA (1) ZA202206807B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN112839707A (zh) * 2019-05-14 2021-05-25 普瑞文森生物有限公司 用于预防i型糖尿病的方法和组合物
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes
CA3159054A1 (en) * 2019-12-06 2021-06-10 Mary S. MORRIS Methods and compositions for the treatment and prevention of type 1 diabetes
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド 1型糖尿病を治療するための方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI923719A0 (fi) * 1992-08-19 1992-08-19 Jaakko Tuomilehto Detektering av susceptibilitet foer diabetes.
EP1755631A2 (en) 2004-03-03 2007-02-28 Diamyd Medical AB Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
CN101687019A (zh) * 2007-04-24 2010-03-31 迪亚米德治疗股份公司 用于治疗自身免疫性疾病和癌症的药物和方法
CN106535926B (zh) * 2014-06-04 2022-02-01 戴尔米德医疗公司 用于基于抗原的疗法的新型组合物
BE1023541B1 (de) 2014-06-05 2017-04-28 Bart Gerard Boucherie Bürstenstopfvorrichtung
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes

Also Published As

Publication number Publication date
JP2023116726A (ja) 2023-08-22
PL3954384T3 (pl) 2025-10-27
IL273016B1 (en) 2024-06-01
KR20230167442A (ko) 2023-12-08
KR20200051737A (ko) 2020-05-13
IL273016B2 (en) 2024-10-01
IL312528A (en) 2024-07-01
EP3954384A1 (en) 2022-02-16
HRP20211989T1 (hr) 2022-03-18
EP3678692B1 (en) 2021-10-20
IL312528B1 (en) 2026-03-01
WO2019050465A1 (en) 2019-03-14
JP2020533306A (ja) 2020-11-19
PT3678692T (pt) 2021-12-29
SMT202500348T1 (it) 2025-11-10
HUE057216T2 (hu) 2022-04-28
EP3678692A1 (en) 2020-07-15
JP7337780B2 (ja) 2023-09-04
KR102607713B1 (ko) 2023-11-29
US20210077587A1 (en) 2021-03-18
JP2024178205A (ja) 2024-12-24
SI3678692T1 (sl) 2022-04-29
DK3678692T3 (da) 2022-01-03
LT3678692T (lt) 2022-01-10
EP3954384B1 (en) 2025-07-02
RS67218B1 (sr) 2025-10-31
KR102781844B1 (ko) 2025-03-14
ES3038990T3 (en) 2025-10-16
HRP20251067T1 (hr) 2025-11-07
HUE072917T2 (hu) 2025-12-28
ZA202206807B (en) 2024-10-30
EP3678692A4 (en) 2021-06-02
ES2902075T3 (es) 2022-03-24
JP7850208B2 (ja) 2026-04-22
CY1124881T1 (el) 2022-11-25
JP7551848B2 (ja) 2024-09-17
EA202090673A1 (ru) 2020-06-23
CN111372602A (zh) 2020-07-03
SMT202200009T1 (it) 2022-03-21
RS62725B1 (sr) 2022-01-31
MX2020002462A (es) 2020-09-22
IL273016A (en) 2020-04-30
CA3074264A1 (en) 2019-03-14
EP3954384C0 (en) 2025-07-02

Similar Documents

Publication Publication Date Title
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
IL257105A (en) Modified cells and methods of therapy
HUE054548T2 (hu) Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
HUE062189T2 (hu) Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
HUE042709T2 (hu) Cukorbetegség és elhízás kezelésére alkalmazható dehidrobenzofurán vegyületek
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PL3678692T3 (pl) Stratyfikacja genotypów w leczeniu i profilaktyce cukrzycy
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
IL258259A (en) Adjunctive therapy with 25-hydroxyvitamin d and articles therefor
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
PL3512517T3 (pl) Stosowanie pridopidyny w leczeniu lęku i depresji
DK3362449T3 (da) Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose
SI3672948T1 (sl) Piridinamin-piridon in spojine pirimidinamin-piridona
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
HUE058314T2 (hu) Pridopidin alkalmazása Rett-szindróma kezelésére
MA50358A (fr) Sémaglutide en thérapie médicale
IL272414A (en) Use of gaboksadol in the treatment of diabetes and related conditions
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
HUE045025T2 (hu) Heterobiciklusos vegyületek és alkalmazásuk tuberkulózis kezelésére
PL3732294T3 (pl) Tymohydrochinon do stosowania w leczeniu hiperglikemii
HUE062784T2 (hu) Indolinon vegyületek és alkalmazásuk fibrotikus betegségek kezelésében
PL3258964T3 (pl) Wykrywanie i leczenie nowotworów złośliwych w oun
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies